NYSE:CTLT - Catalent Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$42.99 +0.25 (+0.58 %)
(As of 09/21/2018 04:15 AM ET)
Previous Close$42.74
Today's Range$42.63 - $43.25
52-Week Range$36.73 - $47.87
Volume806,500 shs
Average Volume953,848 shs
Market Capitalization$6.21 billion
P/E Ratio26.90
Dividend YieldN/A
Beta1.42
Catalent logoCatalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics and Specialty Drug Delivery segment formulates, develops, and manufactures small molecule and biologic drug products in prefilled syringes, vials and cartridges, blow-fill-seal unit doses, and injectable formats; develops biologic cell lines; manufactures biologic drug substances; and offers bioanalytical development and testing services. The Oral Drug Delivery segment formulates, develops, and manufactures oral dosage forms using proprietary and conventional drug delivery technologies, such as Zydis, OptiDose CR, OptiPact, OptiForm API and Solution Suite, Pharmatek SD Spray Drying, OptiMelt hot melt extrusion, Micron particle size reduction, and FlexDose; and provides stick pack formulation and filling, and analytical development and testing services. The Clinical Supply Services segment offers Manufacturing, packaging, labeling, storage, distribution, and inventory management for drugs and biologics clinical trials; FastChain demand-led clinical supply services; clinical e-solutions and informatics; and comparator sourcing services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.

Receive CTLT News and Ratings via Email

Sign-up to receive the latest news and ratings for CTLT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:CTLT
CUSIPN/A
Phone732-537-6200

Debt

Debt-to-Equity Ratio2.44
Current Ratio2.15
Quick Ratio1.79

Price-To-Earnings

Trailing P/E Ratio26.90
Forward P/E Ratio24.99
P/E Growth2.55

Sales & Book Value

Annual Sales$2.46 billion
Price / Sales2.53
Cash Flow$3.0554 per share
Price / Cash14.07
Book Value$8.15 per share
Price / Book5.27

Profitability

EPS (Most Recent Fiscal Year)$1.59
Net Income$83.60 million
Net Margins3.39%
Return on Equity20.42%
Return on Assets4.97%

Miscellaneous

Employees10,700
Outstanding Shares144,870,000
Market Cap$6.21 billion

Catalent (NYSE:CTLT) Frequently Asked Questions

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

How were Catalent's earnings last quarter?

Catalent Inc (NYSE:CTLT) announced its earnings results on Tuesday, August, 28th. The company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.06. The company had revenue of $685.30 million for the quarter, compared to the consensus estimate of $690.69 million. Catalent had a net margin of 3.39% and a return on equity of 20.42%. The company's revenue was up 11.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.65 EPS. View Catalent's Earnings History.

When is Catalent's next earnings date?

Catalent is scheduled to release their next quarterly earnings announcement on Monday, November, 5th 2018. View Earnings Estimates for Catalent.

What guidance has Catalent issued on next quarter's earnings?

Catalent issued an update on its FY18 earnings guidance on Monday, July, 23rd. The company provided earnings per share (EPS) guidance of $1.71-1.75 for the period, compared to the Thomson Reuters consensus estimate of $1.68. The company issued revenue guidance of $2.461-2.464 billion, compared to the consensus revenue estimate of $2.47 billion.Catalent also updated its Q4 guidance to $0.62-0.64 EPS.

What price target have analysts set for CTLT?

12 brokerages have issued 12 month price objectives for Catalent's stock. Their predictions range from $48.00 to $55.00. On average, they expect Catalent's stock price to reach $49.50 in the next year. This suggests a possible upside of 15.1% from the stock's current price. View Analyst Price Targets for Catalent.

What is the consensus analysts' recommendation for Catalent?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalent.

Who are some of Catalent's key competitors?

Who are Catalent's key executives?

Catalent's management team includes the folowing people:
  • Mr. John R. Chiminski, Chairman, Pres & CEO (Age 54)
  • Mr. Steven L. Fasman, Sr. VP, Gen. Counsel & Corp. Sec. (Age 55)
  • Mr. William Downie, Sr. VP of Global Marketing & Sales (Age 51)
  • Mr. Barry B. Littlejohns, Pres of Biologics & Specialty Drug Delivery (Age 52)
  • Mr. Wetteny N. Joseph, Sr. VP & CFO (Age 46)

Has Catalent been receiving favorable news coverage?

News articles about CTLT stock have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Catalent earned a news impact score of 0.18 on Accern's scale. They also assigned headlines about the company an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Catalent.

Who are Catalent's major shareholders?

Catalent's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.85%), Janus Henderson Group PLC (4.80%), FMR LLC (2.61%), American Century Companies Inc. (2.29%), Schroder Investment Management Group (2.22%) and Earnest Partners LLC (1.91%). Company insiders that own Catalent stock include Christine Dolan, Donald E Morel, Jr, John R Chiminski, Sharon Johnson, Steven L Fasman, Uwe Roehrhoff and William Downie. View Institutional Ownership Trends for Catalent.

Which institutional investors are selling Catalent stock?

CTLT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Schroder Investment Management Group, Northern Trust Corp, Wells Fargo & Company MN, Voya Investment Management LLC, OppenheimerFunds Inc., Schroder Investment Management Group and Schwab Charles Investment Management Inc.. Company insiders that have sold Catalent company stock in the last year include John R Chiminski, Steven L Fasman and William Downie. View Insider Buying and Selling for Catalent.

Which institutional investors are buying Catalent stock?

CTLT stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Redmile Group LLC, Macquarie Group Ltd., Paloma Partners Management Co, Janus Henderson Group PLC, Jane Street Group LLC, LMR Partners LLP and American Century Companies Inc.. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr and Uwe Roehrhoff. View Insider Buying and Selling for Catalent.

How do I buy shares of Catalent?

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $42.99.

How big of a company is Catalent?

Catalent has a market capitalization of $6.21 billion and generates $2.46 billion in revenue each year. The company earns $83.60 million in net income (profit) each year or $1.59 on an earnings per share basis. Catalent employs 10,700 workers across the globe.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]


MarketBeat Community Rating for Catalent (NYSE CTLT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  304 (Vote Outperform)
Underperform Votes:  327 (Vote Underperform)
Total Votes:  631
MarketBeat's community ratings are surveys of what our community members think about Catalent and other stocks. Vote "Outperform" if you believe CTLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel